Head and neck for Viralytics
Tuesday, 09 December, 2008
Sydney biotech Viralytics has been authorised to start a trial of its Cavatak oncolytic virus technology in head and neck cancers.
The company is running Phase I trials of the technology in late stage melanoma, prostate and breast cancers.
The new trial will involve nine patients with recurrent, inoperable tumours of the head and neck.
Cavatak is a coxsackievirus-based formulation which attaches itself to receptors on the cell surface that are highly expressed in some solid tumours.
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
